JP2015525230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525230A5 JP2015525230A5 JP2015517364A JP2015517364A JP2015525230A5 JP 2015525230 A5 JP2015525230 A5 JP 2015525230A5 JP 2015517364 A JP2015517364 A JP 2015517364A JP 2015517364 A JP2015517364 A JP 2015517364A JP 2015525230 A5 JP2015525230 A5 JP 2015525230A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- antibody
- optionally
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 15
- 108091000831 antigen binding proteins Proteins 0.000 claims 15
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 206010028289 Muscle atrophy Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000000423 cell based assay Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 108010023082 activin A Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 230000037257 muscle growth Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 102000018918 Activin Receptors Human genes 0.000 claims 1
- 108010052946 Activin Receptors Proteins 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Claims (14)
- (i)SEQ ID NO:15に対して少なくとも97%の同一性を有する第1のポリペプチドおよびSEQ ID NO:16に対して少なくとも97%の配列同一性を有する第2のポリペプチドを含む;
(ii)SEQ ID NO:15およびSEQ ID NO:16を含む;
(iii)2つのアクチビン受容体に結合する;
(iv)SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6、SEQ ID NO:7およびSEQ ID NO:8を含む;
(v)SEQ ID NO:3、SEQ ID NO:4およびSEQ ID NO:5を含む;または
(vi)SEQ ID NO:6、SEQ ID NO:7およびSEQ ID NO:8を含む、
単離された抗原結合タンパク質。 - SEQ ID NO:2およびSEQ ID NO:18に特異的に結合する単離された抗原結合タンパク質であって、任意で、結合すると筋肉の成長を刺激する、請求項1記載の単離された抗原結合タンパク質。
- SEQ ID NO:1およびSEQ ID NO:17に特異的に結合する前記(iii)の単離された抗原結合タンパク質であって、任意で、結合すると筋肉の成長を刺激する、請求項1記載の単離された抗原結合タンパク質。
- (i)モノクローナル抗体もしくはそのフラグメントである;または
(ii)マウス抗体、ヒト化抗体、ヒト抗体、キメラ抗体、多特異性抗体、またはマウス抗体、ヒト化抗体、キメラ抗体もしくは多特異性抗体のフラグメントである、
請求項1〜3のいずれか一項記載の抗原結合タンパク質。 - 請求項1または3記載の抗原結合タンパク質をコードする、単離された核酸。
- 請求項5記載の核酸を含む、発現ベクター。
- 請求項6記載のベクターを含む、宿主細胞であって、任意で、該細胞が真核生物細胞または原核生物細胞であり、任意で、該真核生物細胞が哺乳動物細胞である、宿主細胞。
- 少なくともSEQ ID NO:3〜5またはSEQ ID NO:4〜6を含む、単離された抗原結合タンパク質。
- 抗原結合タンパク質を製造する方法であって、核酸を発現させ抗体を産生させるのに適した条件下で請求項7記載の宿主細胞を培養する工程を含み、任意で、該宿主細胞の培養物から抗体を回収する工程をさらに含む、方法。
- 請求項1または3記載の抗原結合タンパク質、ならびに薬学的に許容される担体、希釈剤または賦形剤を含む、組成物。
- (i)ミオスタチン、アクチビンAまたはGDF-11活性を減少させるまたはブロックする処置が必要な対象においてミオスタチン、アクチビンAまたはGDF-11活性を減少させるまたはブロックする方法に使用するための;
(ii)除脂肪筋肉量を増大させるかまたは脂肪量に対する除脂肪筋肉量の比を増大させる処置が必要な対象において除脂肪筋肉量を増大させるかまたは脂肪量に対する除脂肪筋肉量の比を増大させる方法に使用するための;
(iii)筋消耗疾患の障害に罹患した対象において筋消耗疾患を処置または予防する方法であって、任意で、該筋消耗疾患が、癌性悪液質、筋ジストロフィー、筋萎縮性側索硬化症、うっ血性閉塞性肺疾患、慢性心不全、化学性悪液質(chemical cachexia)、HIV/AIDSに起因する悪液質、腎不全、尿毒症、関節リウマチ、加齢に伴うサルコペニア、加齢に伴う虚弱(age-related frailty)、臓器萎縮(organ atrophy)、手根管症候群、アンドロゲン欠乏、または長時間の床上安静、脊髄損傷、発作、骨折、火傷、加齢もしくはインスリン抵抗性による不活動性に起因する筋消耗を含む、方法に使用するための、
請求項1もしくは3記載の抗原結合タンパク質、または請求項1もしくは3記載の抗原結合タンパク質を含む薬学的組成物。 - (i)BIAcoreアッセイにおいてActRIIBに対して10 pMまたはそれ未満のK D を有し、任意で、ActRIIBに対して1 pMまたはそれ未満のK D を有する;
(ii)BIAcoreアッセイにおいてActRIIAに対して4 nMまたはそれ未満のK D を有し、任意で、ActRIIAに対して1 pMまたはそれ未満のK D も有する;
(iii)細胞ベースのアッセイにおいてActRIIBに対して8 nmまたはそれ未満のIC 50 を有し、任意で、ActRIIBに対して2 nMまたはそれ未満のIC 50 を有する;
(iv)細胞ベースのアッセイにおいてActRIIAに対して2 nMまたはそれ未満のIC 50 を有し、任意で、ActRIIAに対して1 nMまたはそれ未満のIC 50 も有する、
請求項1または3記載の単離された抗原結合タンパク質。 - (i)BIAcoreアッセイにおいてActRIIBおよびActRIIAに対して1 pMまたはそれ未満のK D を有する;または
(ii)細胞ベースのアッセイにおいてActRIIBに対して2 nMまたはそれ未満のIC 50 およびActRIIAに対して1 nMまたはそれ未満のIC 50 を有する、
抗原結合タンパク質。 - アンタゴニスト性デュアル受容体抗体であり、任意で、該デュアル受容体抗体がヒト抗体である、請求項1または3記載の抗原結合タンパク質。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261658237P | 2012-06-11 | 2012-06-11 | |
US61/658,237 | 2012-06-11 | ||
PCT/US2013/045245 WO2013188448A2 (en) | 2012-06-11 | 2013-06-11 | Dual receptor antagonistic antigen-binding proteins and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015525230A JP2015525230A (ja) | 2015-09-03 |
JP2015525230A5 true JP2015525230A5 (ja) | 2016-08-04 |
Family
ID=49758865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015517364A Withdrawn JP2015525230A (ja) | 2012-06-11 | 2013-06-11 | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
Country Status (21)
Country | Link |
---|---|
US (4) | US9453080B2 (ja) |
EP (3) | EP3498857A1 (ja) |
JP (1) | JP2015525230A (ja) |
KR (1) | KR20150030706A (ja) |
CN (1) | CN104540961A (ja) |
AU (1) | AU2013274347B2 (ja) |
BR (1) | BR112014031028A2 (ja) |
CA (1) | CA2877669A1 (ja) |
CL (1) | CL2014003372A1 (ja) |
CO (1) | CO7240399A2 (ja) |
EA (1) | EA201492282A1 (ja) |
HK (1) | HK1208499A1 (ja) |
IL (1) | IL236133A0 (ja) |
MA (1) | MA37761A1 (ja) |
MX (1) | MX2014015195A (ja) |
NZ (1) | NZ703724A (ja) |
PE (1) | PE20150642A1 (ja) |
PH (1) | PH12014502754A1 (ja) |
SG (2) | SG11201408228QA (ja) |
TN (2) | TN2015000448A1 (ja) |
WO (1) | WO2013188448A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201408228QA (en) * | 2012-06-11 | 2015-01-29 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
CN104768969B (zh) | 2012-09-13 | 2021-04-16 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
TW201627007A (zh) * | 2014-12-08 | 2016-08-01 | 諾華公司 | 用於治療肌力退化症之肌肉生長抑制素(myostatin)或活化素(activin)拮抗劑 |
GB201500464D0 (en) * | 2015-01-12 | 2015-02-25 | Crescendo Biolog Ltd | Method of producing optimised therapeutic molecules |
WO2017147182A1 (en) * | 2016-02-22 | 2017-08-31 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
AU2017230091B2 (en) | 2016-03-10 | 2022-04-07 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
EP3593144A1 (en) * | 2017-03-10 | 2020-01-15 | UCL Business Ltd | Method relating to myostatin pathway inhibition |
US11104737B2 (en) | 2017-03-28 | 2021-08-31 | Rigel Pharmaceuticals, Inc. | ACVR2A-specific antibody and method of treatment of muscle atrophy |
KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
CA3087008A1 (en) | 2018-01-12 | 2019-07-18 | Keros Therapeutics, Inc. | Activin receptor type iib variants and methods of use thereof |
JP2022534966A (ja) * | 2019-05-30 | 2022-08-04 | アクセレロン ファーマ インコーポレーテッド | Actrii結合性タンパク質及びその使用 |
EP4121088A1 (en) * | 2020-03-20 | 2023-01-25 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
EP4121090A1 (en) * | 2020-03-20 | 2023-01-25 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CA2407956A1 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
EP2332977B1 (en) * | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
WO2008016356A2 (en) * | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
CN104371024A (zh) | 2008-11-26 | 2015-02-25 | 安姆根有限公司 | 激活素iib受体多肽的变异体及其用途 |
MA33279B1 (fr) | 2009-04-27 | 2012-05-02 | Novartis Ag | Compositions et procédés pour l'augmentation de la croissance des muscles |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
MX358358B (es) | 2011-12-19 | 2018-08-15 | Amgen Inc | Polipeptidos de receptores de activina variantes y sus usos. |
SG11201408228QA (en) * | 2012-06-11 | 2015-01-29 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
-
2013
- 2013-06-11 SG SG11201408228QA patent/SG11201408228QA/en unknown
- 2013-06-11 EP EP18203126.0A patent/EP3498857A1/en active Pending
- 2013-06-11 WO PCT/US2013/045245 patent/WO2013188448A2/en active Application Filing
- 2013-06-11 MA MA37761A patent/MA37761A1/fr unknown
- 2013-06-11 NZ NZ703724A patent/NZ703724A/en not_active IP Right Cessation
- 2013-06-11 CN CN201380042597.XA patent/CN104540961A/zh active Pending
- 2013-06-11 EP EP13804428.4A patent/EP2859114B1/en active Active
- 2013-06-11 PE PE2014002415A patent/PE20150642A1/es not_active Application Discontinuation
- 2013-06-11 JP JP2015517364A patent/JP2015525230A/ja not_active Withdrawn
- 2013-06-11 EA EA201492282A patent/EA201492282A1/ru unknown
- 2013-06-11 MX MX2014015195A patent/MX2014015195A/es unknown
- 2013-06-11 SG SG10201610356YA patent/SG10201610356YA/en unknown
- 2013-06-11 TN TN2015000448A patent/TN2015000448A1/en unknown
- 2013-06-11 CA CA2877669A patent/CA2877669A1/en not_active Abandoned
- 2013-06-11 AU AU2013274347A patent/AU2013274347B2/en not_active Expired - Fee Related
- 2013-06-11 EP EP19169804.2A patent/EP3540070A1/en active Pending
- 2013-06-11 KR KR1020157000579A patent/KR20150030706A/ko not_active Application Discontinuation
- 2013-06-11 US US14/407,421 patent/US9453080B2/en active Active
- 2013-06-11 BR BR112014031028A patent/BR112014031028A2/pt not_active IP Right Cessation
-
2014
- 2014-12-08 IL IL236133A patent/IL236133A0/en unknown
- 2014-12-09 PH PH12014502754A patent/PH12014502754A1/en unknown
- 2014-12-10 TN TN2014000513A patent/TN2014000513A1/fr unknown
- 2014-12-11 CL CL2014003372A patent/CL2014003372A1/es unknown
-
2015
- 2015-01-08 CO CO15003908A patent/CO7240399A2/es unknown
- 2015-09-14 HK HK15108981.7A patent/HK1208499A1/xx unknown
-
2016
- 2016-08-25 US US15/247,792 patent/US10266598B2/en active Active
-
2019
- 2019-03-05 US US16/293,254 patent/US10981999B2/en active Active
-
2021
- 2021-03-18 US US17/205,144 patent/US20210340262A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015525230A5 (ja) | ||
HRP20201729T1 (hr) | Antitijela protiv aktivina a i njihova primjena | |
EA201590138A1 (ru) | Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение | |
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
NO20210499A1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
JP2016539096A5 (ja) | ||
JP2020536488A (ja) | 抗cd47抗体及びその使用 | |
JP2020503001A5 (ja) | ||
JP2024012308A (ja) | 抗lag-3抗体の投薬量レジメンおよびその使用 | |
JP2018535196A5 (ja) | ||
JP2020517635A5 (ja) | ||
JP2019510739A5 (ja) | ||
JP2016500251A5 (ja) | ||
JP2014526898A5 (ja) | ||
JP2019513777A5 (ja) | ||
JP2008530138A5 (ja) | ||
WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
JP2014503189A5 (ja) | ||
JP2012070740A5 (ja) | ||
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
EA201390278A1 (ru) | Антитела к ох40 и способы их применения | |
JP2014158480A5 (ja) | ||
WO2006082515A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
MX2012002461A (es) | Anticuerpos del antigeno carcinoembrionario (cea). | |
JP2016523910A5 (ja) |